Medidata Solutions Inc (NASDAQ:MDSO) has been assigned a consensus rating of “Buy” from the seventeen analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $83.00.
A number of analysts have recently commented on the company. TheStreet upgraded Medidata Solutions from a “c+” rating to a “b-” rating in a report on Monday, March 12th. BidaskClub upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. ValuEngine lowered Medidata Solutions from a “hold” rating to a “sell” rating in a report on Saturday, March 17th. Wells Fargo upgraded Medidata Solutions from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a report on Friday, December 1st. Finally, Zacks Investment Research lowered Medidata Solutions from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th.
MDSO stock opened at $62.81 on Wednesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.49 and a current ratio of 1.49. The stock has a market cap of $3,720.44, a price-to-earnings ratio of 73.89, a price-to-earnings-growth ratio of 3.30 and a beta of 1.56. Medidata Solutions has a 1-year low of $56.14 and a 1-year high of $85.92.
In related news, CEO Tarek Sherif sold 26,836 shares of Medidata Solutions stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $70.25, for a total value of $1,885,229.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $66.30, for a total value of $132,600.00. Following the completion of the sale, the chief financial officer now directly owns 94,744 shares in the company, valued at approximately $6,281,527.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,836 shares of company stock worth $2,495,689. 5.80% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Summit Creek Advisors LLC acquired a new stake in shares of Medidata Solutions in the fourth quarter valued at about $5,137,000. AMP Capital Investors Ltd acquired a new position in Medidata Solutions during the third quarter worth approximately $2,194,000. KAMES CAPITAL plc increased its position in Medidata Solutions by 54.6% during the fourth quarter. KAMES CAPITAL plc now owns 25,521 shares of the company’s stock worth $1,617,000 after buying an additional 9,012 shares during the last quarter. Zions Bancorporation acquired a new position in Medidata Solutions during the third quarter worth approximately $256,000. Finally, Schwab Charles Investment Management Inc. increased its position in Medidata Solutions by 38.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 326,950 shares of the company’s stock worth $25,522,000 after buying an additional 90,572 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.